Disease Modifying Therapy in Multiple Sclerosis

Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal degeneration. It is the commonest cause of permanent disability in young adults. Environmental and genetic factors have been suggested in its etiology. Currently available...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, U. E., Oparah, S. K., Philip-Ephraim, E. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897446/
https://www.ncbi.nlm.nih.gov/pubmed/27355035
http://dx.doi.org/10.1155/2014/307064
_version_ 1782436161165197312
author Williams, U. E.
Oparah, S. K.
Philip-Ephraim, E. E.
author_facet Williams, U. E.
Oparah, S. K.
Philip-Ephraim, E. E.
author_sort Williams, U. E.
collection PubMed
description Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal degeneration. It is the commonest cause of permanent disability in young adults. Environmental and genetic factors have been suggested in its etiology. Currently available disease modifying drugs are only effective in controlling inflammation but not prevention of neurodegeneration or accumulation of disability. Search for an effective neuroprotective therapy is at the forefront of multiple sclerosis research.
format Online
Article
Text
id pubmed-4897446
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48974462016-06-28 Disease Modifying Therapy in Multiple Sclerosis Williams, U. E. Oparah, S. K. Philip-Ephraim, E. E. Int Sch Res Notices Review Article Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory demyelination and axonal degeneration. It is the commonest cause of permanent disability in young adults. Environmental and genetic factors have been suggested in its etiology. Currently available disease modifying drugs are only effective in controlling inflammation but not prevention of neurodegeneration or accumulation of disability. Search for an effective neuroprotective therapy is at the forefront of multiple sclerosis research. Hindawi Publishing Corporation 2014-07-07 /pmc/articles/PMC4897446/ /pubmed/27355035 http://dx.doi.org/10.1155/2014/307064 Text en Copyright © 2014 U. E. Williams et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Williams, U. E.
Oparah, S. K.
Philip-Ephraim, E. E.
Disease Modifying Therapy in Multiple Sclerosis
title Disease Modifying Therapy in Multiple Sclerosis
title_full Disease Modifying Therapy in Multiple Sclerosis
title_fullStr Disease Modifying Therapy in Multiple Sclerosis
title_full_unstemmed Disease Modifying Therapy in Multiple Sclerosis
title_short Disease Modifying Therapy in Multiple Sclerosis
title_sort disease modifying therapy in multiple sclerosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897446/
https://www.ncbi.nlm.nih.gov/pubmed/27355035
http://dx.doi.org/10.1155/2014/307064
work_keys_str_mv AT williamsue diseasemodifyingtherapyinmultiplesclerosis
AT oparahsk diseasemodifyingtherapyinmultiplesclerosis
AT philipephraimee diseasemodifyingtherapyinmultiplesclerosis

Ejemplares similares